Friday, April 16

“If we do not end the coronavirus all over the planet, it will mutate and threaten again”


“Vaccines cannot be delayed due to lack of resources,” emphasizes the Alicante researcher. «It does not seem acceptable that vaccine manufacturing is delayed because a production line in a factory fails or because resources are lacking. Every day that our economy is paralyzed, we lose more money than it would cost us to put in the necessary resources so that the production and distribution of vaccines were not a problem, “he adds.

The alert message launched by Javier García, qualifies as a “serious error” that after having managed to develop several vaccines effective against covid-19 in just 10 months, the vaccination of the population is being so slow.

Emergency

To overcome what he qualifies as one of the biggest emergencies in recent years, he stresses that government and companies must work together. “We have misunderstood public-private collaboration to solve one of humanity’s greatest crises. The great challenges of our time, from the fight against diseases to climate change, require this public-private collaboration, “he insists.

The current model does not seem efficient to him because it is creating tensions between the countries that, instead of collaborating, “compete to get hold of the few units available,” laments the professor at the University of Alicante, while proposing a “more collaborative model »To overcome this challenge.

“There are no financial or technical reasons that prevent accelerating the production of vaccines”

JAVIER GARCÍA – INORGANIC CHEMICAL CATHEDRATIC, UA


decoration

With all the industry and research at your service, you understand that Governments should encourage vaccines to reach the whole world, as he recalls that smallpox was eradicated in 1980. “From past mistakes we have learned that if we do not end a disease on the entire planet, we give it the opportunity to evolve and become more resistant. The covid It is capable of mutating and this reinforces the need to end it as soon as possible, ”he insists.

The professor of Inorganic Chemistry from the UA emphasizes that Science is providing innovative solutions, such as vaccines against coronavirus. And it highlights the contributions of Chemistry: «Disinfectants, antibiotics, drugs and chemical substances. Without going any further, the genetic material that is the basis of some of the vaccines against covid-19, is transported in nanocapsules made with lipid molecules. Vaccines also contain aluminum salts that increase your immune response, allowing you to reduce the dose to protect yourself. And they contain magnesium salts that stabilize the vaccine so that it lasts longer. There is a lot of chemistry in vaccines, ”García abounds.

But what he does not conceive from the International Chemical Union that he presides, is that the use is not in turn the maximum because at some point in the production some component may be missing, something that would solve the public-private collaboration that is historically required in situations of emergency.

Tension

The European Union estimates that by early 2022 it will be possible to manufacture between 2,000 and 3,000 million doses per year. According to the European Federation of Pharmaceutical Industries and Associations, there are about 60 factories around the world capable of producing covid-19 vaccines, 20 of them in Europe. Javier García emphasizes that “contracts are not the most appropriate way to resolve a health emergency. Governments and businesses need to work together so that the necessary resources and regulation are not lacking. ‘

He does not see any “technical or financial” reason that prevents accelerating vaccine production, and considers that “competing for the highest bidder for a scarce resource creates mistrust.” The researcher concludes that this way of proceeding “frankly, is not helping.”

Disputes that can end in lawsuits “and it will be too late”

European vaccines include up to 400 different components, in whose production more than 100 companies participate, but the existence of tensions due to the shortage of ingredients to manufacture them, problems in production lines and coordination is recognized. This was stated by the European Commissioner for the Internal Market and Industry, Thierry Breton, in the first visit of journalists to the Pfizer vaccine manufacturing plant in Belgium. In this regard, the professor at the University of Alicante, Javier García, values ​​that “it is very likely that some of the disputes between companies and the European Commission will end in court, but then it will be too late for the thousands of people who go to fall ill due to delays in the vaccination process, “he concludes.


www.informacion.es

Leave a Reply

Your email address will not be published. Required fields are marked *